mibefradil has been researched along with Angor Pectoris in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 28 (77.78) | 18.2507 |
| 2000's | 8 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beltrame, JF; Ganz, P | 1 |
| Beltrame, JF; Horowitz, JD; Leslie, S; Turner, SP | 1 |
| Bakx, AL; Braun, S; Bruschke, AV; Emanuelsson, H; Kobrin, I; van der Wall, EE | 1 |
| Braun, S; Emanuelsson, H; Kobrin, I; van der Wall, EE | 1 |
| Alpert, JS; DeQuattro, V; Fenster, PE; Friedman, R; Kobrin, I; Shepherd, A; Thadani, U | 1 |
| Alpert, JS; Bakx, AL; Braun, S; Frishman, WH; Kobrin, I; Schneeweiss, A; Tzivoni, D | 1 |
| Davies, GJ; Kobrin, I; Tzivoni, D | 1 |
| Charlon, V; Kobrin, I; Lindberg, E; Pordy, R | 1 |
| Armagnijan, D; Caspi, A; Coelho, OR; Davies, GJ; de Albuquerque, DC; Kobrin, I; Reisin, LH; Schneeweiss, A | 1 |
| Braat, S; Kadr, H; Kobrin, I; Ramires, JA; Rutsch, W; Tzivoni, D | 1 |
| Brogden, RN; Markham, A | 1 |
| Giles, TD | 1 |
| Massie, BM | 2 |
| Pitt, B | 1 |
| Hermsmeyer, K; Minshall, R; Mishra, S; Miyagawa, K | 1 |
| Kobrin, I | 1 |
| Caspi, A; Charlon, V; Kobrin, I; Marmor, A; Reisin, L; Schlesinger, Z; Schneeweiss, A; Sclarovsky, S | 1 |
| Alpert, JS | 1 |
| Bieska, G; Charlon, V; Kobrin, I; Lindberg, E; Pordy, R | 1 |
| Billups, SJ; Carter, BL | 1 |
| Bittar, N; Frishman, WH; Glasser, S; Habib, G; Pordy, R; Smith, W | 1 |
| Charlon, V; Kobrin, I | 1 |
| Cleophas, TJ; Daniëls, MC; Hendriks, MG; Holwerda, NJ; Schelling, A; Van Der Vring, JA; Withagen, PJ | 2 |
| Cleophas, TJ; Daniëls, MC; Hendriks, MG; Holwerda, KJ; Schelling, A; van der Sluijs, J; van der Vring, JA; Withagen, AJ; Zwinderman, AH | 1 |
| Botvin, S; Gilula, Z; Klutstein, MW; Kobrin, I; Reisin, L; Tzivoni, D | 1 |
| Gläser, S; Kleber, FX; Opitz, C; Steinbach, M; Wruck, U | 1 |
| Fischer Hansen, J; Grande, P; Gustafsson, I; Hassager, C; Mickley, H; Skagen, K; Steensgaard-Hansen, F; Thygesen, K | 1 |
| Riley, J; Shakir, SA; Wilton, LV | 1 |
| Thadani, U | 1 |
| Dean, DM; Gervais, PB; Goodman, S; Langer, A; Lee, DS; Lenis, J; Ma, P | 1 |
| Braat, SH; Gassner, A; Hagemeijer, F; Kraaij, CJ; Portegies, MC; Pozenel, H; Prager, G; Schmitt, R; van der Wall, EE; Viersma, JW | 1 |
8 review(s) available for mibefradil and Angor Pectoris
| Article | Year |
|---|---|
Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Half-Life; Hemodynamics; Humans; Hypertension; Mibefradil; Molecular Structure; Myocardial Contraction; Tetrahydronaphthalenes | 1997 |
Mibefradil (posicor).
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Mibefradil; Tetrahydronaphthalenes; Treatment Outcome | 1997 |
Mibefradil: a selective T-type calcium antagonist.
Topics: Angina Pectoris; Animals; Benzimidazoles; Calcium Channel Blockers; Heart Failure; Humans; Hypertension; Mibefradil; Structure-Activity Relationship; Tetrahydronaphthalenes | 1997 |
Diversity of calcium antagonists.
Topics: Angina Pectoris; Arteriosclerosis; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Humans; Hypertension; Kidney Failure, Chronic; Mibefradil; Nifedipine; Tetrahydronaphthalenes; Verapamil | 1997 |
Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists.
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Calcium Channels; Cardiovascular Physiological Phenomena; Humans; Hypertension; Mibefradil; Tetrahydronaphthalenes | 1997 |
Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Topics: Adolescent; Adult; Amlodipine; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia; Safety; Tetrahydronaphthalenes | 1998 |
Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Diltiazem; Humans; Mibefradil; Tetrahydronaphthalenes | 1998 |
Mibefradil: a new class of calcium-channel antagonists.
Topics: Aged; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Mibefradil; Tetrahydronaphthalenes | 1998 |
21 trial(s) available for mibefradil and Angor Pectoris
| Article | Year |
|---|---|
Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Topics: Adult; Aged; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Placebos; Tetrahydronaphthalenes; Time Factors | 1995 |
Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Topics: Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia; Tetrahydronaphthalenes | 1996 |
Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Exercise Test; Female; Humans; Male; Mibefradil; Middle Aged; Tetrahydronaphthalenes; Treatment Outcome; Vasodilator Agents | 1997 |
Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Exercise Test; Female; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia; Tetrahydronaphthalenes | 1997 |
Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Diltiazem; Female; Hemodynamics; Humans; Male; Mibefradil; Middle Aged; Nitroglycerin; Tetrahydronaphthalenes | 1997 |
Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Topics: Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Drug Administration Schedule; Electrocardiography; Female; Heart Conduction System; Heart Rate; Humans; Hypertension; Male; Mibefradil; Middle Aged; Nifedipine; Tetrahydronaphthalenes | 1997 |
Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
Topics: Adult; Aged; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Delayed-Action Preparations; Diltiazem; Double-Blind Method; Exercise Test; Female; Hemodynamics; Humans; Male; Mibefradil; Middle Aged; Nitroglycerin; Prospective Studies; Tetrahydronaphthalenes | 1997 |
Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Double-Blind Method; Electrocardiography, Ambulatory; Exercise; Exercise Test; Female; Heart Rate; Hemodynamics; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia; Nitroglycerin; Prospective Studies; Tetrahydronaphthalenes; Vasodilator Agents | 1997 |
Differential properties of mibefradil in hypertension and angina.
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Double-Blind Method; Heart Rate; Humans; Hypertension; Mibefradil; Nifedipine; Tetrahydronaphthalenes | 1997 |
Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Female; Humans; Male; Mibefradil; Middle Aged; Tetrahydronaphthalenes; Time Factors | 1998 |
Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Exercise Tolerance; Humans; Mibefradil; Propranolol; Safety; Tetrahydronaphthalenes; Treatment Outcome | 1998 |
Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Topics: Adolescent; Adult; Amlodipine; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia; Safety; Tetrahydronaphthalenes | 1998 |
Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Mibefradil; Middle Aged; Nitroglycerin; Prospective Studies; Safety; Tetrahydronaphthalenes; Treatment Outcome; Vasodilator Agents | 1998 |
The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Benzimidazoles; Body Weight; Calcium Channel Blockers; Chronic Disease; Exercise Test; Female; Humans; Male; Mibefradil; Middle Aged; Sex Factors; Tetrahydronaphthalenes; Treatment Outcome | 1998 |
Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascul
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Diltiazem; Dizziness; Double-Blind Method; Drug Therapy, Combination; Exercise; Exercise Test; Female; Heart Rate; Hemodynamics; Humans; Male; Mibefradil; Middle Aged; Risk Assessment; Tetrahydronaphthalenes | 1999 |
Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Resear
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Diltiazem; Dizziness; Double-Blind Method; Drug Combinations; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia; Physical Exertion; Tetrahydronaphthalenes; Time Factors | 1999 |
Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Death, Sudden; Diltiazem; Dizziness; Double-Blind Method; Drug Therapy, Combination; Exercise; Exercise Test; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Regression Analysis; Tetrahydronaphthalenes; Treatment Outcome | 1999 |
The effect of mibefradil on ischemic episodes with and without increase in heart rate.
Topics: Angina Pectoris; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia | 2000 |
Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Atenolol; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Diastole; Double-Blind Method; Echocardiography, Doppler; Female; Heart Rate; Heart Septum; Humans; Male; Mibefradil; Middle Aged; Mitral Valve; Time Factors; Ventricular Function, Left | 2001 |
Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.
Topics: Angina Pectoris; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Diltiazem; Double-Blind Method; Female; Humans; Male; Mibefradil; Middle Aged; Myocardial Ischemia | 2002 |
Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Depression, Chemical; Double-Blind Method; Electrocardiography; Erythrocytes; Exercise Test; Female; Heart Rate; Humans; Male; Mibefradil; Middle Aged; Myocardial Contraction; Radionuclide Ventriculography; Tetrahydronaphthalenes; Ventricular Function, Left | 1991 |
8 other study(ies) available for mibefradil and Angor Pectoris
| Article | Year |
|---|---|
Evaluating patients with persistent chest pain and no obstructive coronary artery disease.
Topics: Angina Pectoris; Animals; Blood Flow Velocity; Cardiovascular Agents; Chest Pain; Coronary Circulation; Coronary Disease; Diagnosis, Differential; Humans; Mibefradil; Quality of Life; Randomized Controlled Trials as Topic; Rest; Vasodilator Agents | 2009 |
Mibefradil: "Has the baby been thrown out with the bath water?".
Topics: Angina Pectoris; Calcium Channel Blockers; Calcium Channels, T-Type; Coronary Disease; Coronary Vessels; Drug and Narcotic Control; Humans; Mibefradil; Randomized Controlled Trials as Topic; Verapamil | 2003 |
[Mibefradil opens up a new class of calcium antagonists. Glasgow, 23 June 1996].
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Humans; Hypertension; Mibefradil; Tetrahydronaphthalenes | 1996 |
Mibefradil--a new calcium-channel blocker.
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Clinical Trials as Topic; Contraindications; Drug Administration Schedule; Drug Interactions; Humans; Hypertension; Mibefradil; Tetrahydronaphthalenes | 1997 |
[Mibefradil: a new class calcium inhibitor].
Topics: Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Humans; Hypertension; Mibefradil; Tetrahydronaphthalenes | 1996 |
Torsades de pointes caused by Mibefradil.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Female; Humans; Hypertension; Long QT Syndrome; Mibefradil; Tachycardia, Ventricular; Torsades de Pointes | 2001 |
A post-marketing observational study to assess the safety of mibefradil in the community in England.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina Pectoris; Calcium Channel Blockers; Dizziness; Drug and Narcotic Control; Drug Interactions; Edema; England; Fatigue; Female; Headache; Humans; Hypertension; Male; Mibefradil; Middle Aged; Product Surveillance, Postmarketing | 2002 |
Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris.
Topics: Angina Pectoris; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Diltiazem; Humans; Mibefradil; Myocardial Ischemia | 2002 |